We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Gilding the Lilly

16 November 2006 By Robert Cyran

Rebels have a strong case, they argue the biotech has agreed to sell itself for a dirt cheap $1.1bn pricetag to Eli Lilly. The problem is a familiar one in biotech Lilly is the only likely buyer.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)